€100m market cap
€1.88 last close
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Its main product, BARHEMSYS, is for the treatment of PONV and is forecast to launch in 2019.
Investment summary
Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia’s lead product BARHEMSYS (repurposed amisulpride for the management of PONV) has been resubmitted to the FDA following receipt of a CRL (in October) relating to deficiencies at the contract manufacturer. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal to review the class 2 resubmission by 5 May 2019, but we highlight this could be delayed by the US government shutdown. We still anticipate a US launch of BARHEMSYS in Q219 for PONV ‘rescue treatment’ and expect broadening of use for PONV prophylaxis in subsequent years. As of 31 December, Acacia had net cash of £22.1m.
Y/E Dec |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.0 | (3.0) | (6.5) | (2.32) | N/A | N/A |
| 2018A | 0.0 | (15.0) | (16.2) | (0.35) | N/A | N/A |
| 2019E | 1.1 | (43.7) | (46.0) | (0.83) | N/A | N/A |
| 2020E | 13.5 | (39.2) | (41.7) | (0.76) | N/A | N/A |
| Last updated on 22/03/2019 | ||||||
Industry outlook
Inadequately treated PONV leads to prolonged stay in post-anaesthesia care unit (PACU) recovery rooms. BARHEMSYS use could reduce patient hospitalisation time and the associated costs.
Last updated on 22/03/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (£m) | 5.6 |
| Forecast gearing ratio (%) | 0 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Julian Gilbert | CEO |
| Christine Soden | CFO |
You may also be interested in…
- 4SC
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma